Generate a tailored SOP for Dr. Kathrin Schumann. Improve your application with a focused, well-structured draft.
Professor Kathrin Schumann focuses on human immune cell engineering, utilizing innovative CRISPR technology to modify genetic regions within human T cells and characterize their stability and cellular function. Her long-term goal is to develop new therapies for the treatment of autoimmune diseases and cancer. She studied biochemistry at the University of Tübingen and obtained her PhD from the Max Planck Institute of Biochemistry in Martinsried. During her career, she has conducted research at the Novartis Institutes for Biomedical Research in Basel and the University of California, San Francisco, where she worked in laboratories led by Alex Marson and Jeffrey Bluestone. In 2018, she was appointed as a Rudolf Mößbauer Tenure Track Assistant Professor in Engineering Immune Cells Therapy at the Technical University of Munich's School of Medicine.
Technical University of Munich • Munich, Germany
Leading research in engineering immune cells using CRISPR technology.